These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25367954)

  • 1. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
    Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
    Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where exactly does ponatinib fit in chronic myelogenous leukemia?
    Berman E
    J Natl Compr Canc Netw; 2014 Nov; 12(11):1615-20. PubMed ID: 25361807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 8. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
    Deininger MW; Hodgson JG; Shah NP; Cortes JE; Kim DW; Nicolini FE; Talpaz M; Baccarani M; Müller MC; Li J; Parker WT; Lustgarten S; Clackson T; Haluska FG; Guilhot F; Kantarjian HM; Soverini S; Hochhaus A; Hughes TP; Rivera VM; Branford S
    Blood; 2016 Feb; 127(6):703-12. PubMed ID: 26603839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
    Shah NP
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
    [No Abstract]   [Full Text] [Related]  

  • 10. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
    Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
    EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
    Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
    PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
    Frankfurt O; Licht JD
    Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL1 mutation ≠ ponatinib resistance.
    Saglio G; Fava C
    Blood; 2016 Feb; 127(6):666-7. PubMed ID: 26869304
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
    Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
    Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
    Thomas X
    Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.